Paxlovid Study Results In
Pfizer’s Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study

The study enrolled adult vaccinated patients with COVID-19 who had at least one risk factor for severe disease and patients without risk factors who had never been vaccinated or had not received a vaccine in the past year.

*The median time to sustained alleviation of all targeted signs and symptoms of COVID-19 was 12 days in the Paxlovid group and 13 days in the placebo group (P=0.60). *

  • “Clearly, the benefit observed among unvaccinated high-risk persons does not extend to those at lower risk for severe COVID-19. This result supports guidelines that recommend nirmatrelvir–ritonavir only for persons who are at high risk for disease progression.”*